THE JOINT CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.65 USD | -0.87% |
|
-2.29% | +42.04% |
| 13/05 | The Joint Engages Capstone Partners to Expedite Refranchising | MT |
| 06/05 | B. Riley Adjusts Price Target on Joint to $20 From $12, Maintains Buy Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 95.79 times its estimated earnings per share for the ongoing year.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +42.04% | 20Cr | C+ | ||
| +25.79% | 8.92TCr | C+ | ||
| -23.21% | 7.61TCr | B- | ||
| +1.62% | 2.71TCr | C+ | ||
| -10.58% | 1.71TCr | B | ||
| -0.29% | 1.68TCr | A- | ||
| +0.52% | 1.54TCr | A- | ||
| +77.83% | 1.37TCr | C- | ||
| +79.56% | 1.33TCr | C+ | ||
| -25.79% | 1.28TCr | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- JYNT Stock
- Ratings The Joint Corp.
